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AbstrACt
Introduction The first- line recommended treatment for 
patients with intermittent claudication (IC) is a supervised 
exercise programme (SEP), which includes a minimum 
of 2- hours of exercise per week over a 12- week period. 
However, provision, uptake and adherence rates for these 
SEP programmes are poor, with time constraints cited 
as a common participant barrier. High- intensity interval 
training (HIIT) is more time- efficient and therefore has 
the potential to overcome this barrier. However, evidence 
is lacking for the role of HIIT in those with IC. This proof- 
of- concept study aims to consider the safety, feasibility, 
tolerability and acceptability of a HIIT programme for 
patients with IC.
Methods and analysis This multicentre, single- 
group, prospective, interventional feasibility study will 
recruit 40 patients with IC, who will complete 6 weeks 
of HIIT, 3 times a week. HIIT will involve a supervised 
programme of 10×1 min high- intensity cycling intervals 
at 85%–90% peak power output (PPO), interspaced with 
10×1 min low intensity intervals at 20%–25% PPO. PPO 
will be determined from a baseline cardiopulmonary 
exercise test (CPET) and it is intended that patients will 
achieve ≥85% of maximum heart rate from CPET, by 
the end of the second HIIT interval. Primary outcome 
measures are safety (occurrence of adverse events directly 
related to the study), programme feasibility (including 
participant eligibility, recruitment and completion rates) 
and HIIT tolerability (ability to achieve and maintain the 
required intensity). Secondary outcomes include patient 
acceptability, walking distance, CPET cardiorespiratory 
fitness measures and quality of life outcomes.
Ethics and dissemination Ethical approval was obtained 
via a local National Health Service research ethics 
committee (Bradford Leeds – 18/YH/0112) and recruitment 
began in August 2019 and will be completed in October 
2020. Results will be published in peer- reviewed journals 
and presented at international conferences and are 
expected to inform a future pilot randomised controlled 
trial of HIIT versus usual- care SEPs.
trial registration number NCT04042311; Pre- results.
IntroduCtIon
Peripheral arterial disease (PAD) is caused 
by atherosclerotic lesions in the arteries 
supplying the lower limbs, reducing blood 
flow.1 PAD is relatively common, age- 
dependent and increasing in its prevalence. 
In 2010, it was estimated that PAD affected 
202 million people globally, with those aged 
75 or older having an approximately eight-
fold risk compared with those aged less than 
60.2 3 Compounded by population ageing 
and an increase in the prevalence of diabetes, 
it was estimated that the number of people 
living with PAD increased over the previous 
decade by 13% and 29% in high- income and 
low- middle- income countries, respectively.3
Symptomatic PAD typically presents as 
intermittent claudication (IC), defined as a 
reproducible ambulatory leg pain, in the calf 
and/or thigh and/or buttocks, caused by an 
oxygen supply–demand imbalance, relieved 
by rest.4 5 As such, IC negatively impacts on 
walking ability, functional capacity, quality 
of life (QoL) and daily activities, while also 
leading to a markedly increased mortality 
strengths and limitations of this study
 ► This study will assess the safety and feasibility of a 
novel, pragmatic high- intensity interval training pro-
gramme for patients with intermittent claudication.
 ► It will also consider acceptability of the programme 
via qualitative methods of patient feedback.
 ► As a limitation, due to the single- group design it is 
not possible to identify if patients who choose to 
take part in this study are simply those who would 
have also chosen to take part in a usual- care exer-
cise programme.
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risk.6–11 The recommended treatment strategy for IC is 
non- invasive and includes pharmacological risk factor 
management and exercise therapy, via a supervised exer-
cise programme (SEP).12–14 SEPs should consist of a 
minimum of 2- hours of exercise per week for a 12- week 
period, with patients encouraged to exercise to the point 
of maximal pain.12 SEPs are supported by high- quality 
evidence for their clinical and cost- effectiveness,15 with 
evidence also suggesting that SEPs are equal to primary 
stenting for symptomatic improvement, which is main-
tained for a year after programme completion.16 17
Despite the irrefutable evidence for the benefit of SEPs, 
just 39% of UK vascular centres provide access to one,18 
and for those that do, uptake and completion rates are 
suboptimal. One review demonstrated that only 25% 
of screened patients are recruited to a programme,19 
with time cited as the most common barrier for partic-
ipation.20 Furthermore, the current recommendations 
for SEPs appear to adopt a ‘one size fits all’ approach 
which is not based on any objective measure of functional 
capacity, potentially limiting physiological and symptom-
atic benefits. One alternative that is both time- efficient 
and prescribed based on the gold- standard measure 
of cardiopulmonary exercise testing (CPET), is high- 
intensity interval training (HIIT). HIIT, therefore, has the 
potential to overcome the previously cited programme- 
related drawbacks of traditional SEP. HIIT has demon-
strated similar or superior benefits, when compared with 
traditionally prescribed exercise, in patients with coro-
nary artery disease, chronic heart failure, hypertension, 
obesity and metabolic syndrome characteristics.21–24 HIIT 
has been highlighted as a potentially preferred treat-
ment option in those with IC, though the evidence in 
this population is much more limited.20 Initial systematic 
review evidence has indicated that HIIT has the poten-
tial to provide clinical and symptomatic benefits, though 
there was significant heterogeneity between published 
studies in terms of HIIT modality, frequency, intensity 
and duration.25 The authors recommended that future 
appropriately designed studies consider shorter- term and 
low- volume HIIT programmes for patients with IC.
Therefore, the aim of this multicentre proof- of- 
concept study is to consider the safety, tolerability, feasi-
bility and acceptability of a short- term, low- volume HIIT 
programme in those with IC.
MEthods And AnAlysIs
High Intensity Interval Training In pATiEnts With Inter-
mittent Claudication (INITIATE) is a pragmatic, single- 
group, multicentre and prospective interventional 
proof- of- concept study. The study design and inclusion/
exclusion criteria have been informed by a previous, 
single- centre study including 30 patients.26
For this study, participants will be recruited consecutively 
and perform 6 weeks of HIIT. Study interventions and 
outcome assessments will be conducted by research staff 
that due to the nature of the study cannot be blinded. This 
protocol adheres to the Standard Protocol Items: Recom-
mendations for Clinical Trials (SPIRIT) guidelines, and we 
used the SPIRIT checklist when writing this protocol.27 28
setting
INITIATE will be conducted at two UK centres; 1. The 
Academic Vascular Surgical Unit, Hull Royal Infirmary, 
Kingston- Upon- Hull and 2. Atrium Health, Centre for 
Exercise and Health, Coventry and Warwickshire Hospi-
tals National Health Service (NHS) Trust, Coventry. Spon-
sorship is provided by Hull University Teaching Hospitals 
NHS Trust and funding provided by the National Insti-
tute for Health Research, Research for Patient Benefit 
programme. Recruitment commenced in August 2019, 
with a recruitment target of 40 patients (20 per site). 
Recruitment is anticipated to be completed by October 
2020.
study registration
The study was prospectively registered on  ClinicalTrials. 
gov and the study registration data set is given in table 1. 
Any amendments required to this protocol will seek 
approvals from the research ethics committee and will be 
outlined (with reasons) in the final published report.
how the sample will be selected
This study will recruit patients with IC secondary to PAD 
referred to a usual- care SEP, with a confirmed diagnosis of 
IC by resting and/or postexercise ankle- brachial pressure 
index (ABPI) and/or documented significant atheroscle-
rosis on radiological imaging.
Inclusion criteria
 ► Aged≥18 years.
 ► ABPI<0.9 at rest or a systolic pressure drop of ≥20 mm 
Hg at the ankle after exercise testing.
 ► Ability to walk unaided.
 ► English speaking and able to comply with exercise 
instructions.
Exclusion criteria
 ► Unable to provide informed consent.
 ► Critical limb threatening ischaemia/rest pain/tissue 
loss.
 ► Active cancer treatment.
 ► Significant comorbidities precluding safe participa-
tion in exercise testing and/or training according to 
the American College of Sports Medicine (ACSM) 
guidelines.29
 ► Resting/uncontrolled tachycardia (>100 bpm) and/
or resting/uncontrolled hypertension (systolic 
blood pressure>180 mm Hg or diastolic blood pres-
sure>100 mm Hg).
 ► Symptomatic hypotension.
Additional exclusion criteria
Following baseline CPET, patients will be withdrawn and 
prevented from continuing their involvement in the study 
if there is any evidence of:
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Table 1 Study registration items
Data category Information
Primary registry and 
identifying number
ClinicalTrials.gov NCT04042311 (Workstream 2)
Date of registration in 
primary registry
01/08/2019
Source of monetary or 
material support
National Institute for Health Research, Research for Patient Benefit programme
Primary Sponsor Hull University Teaching Hospitals NHS Trust
Contact for public queries JL (Judith.Long@hey.nhs.uk)
Contact for scientific queries SP (Sean.Pymer@hey.nhs.uk)
Public title High INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE)
Scientific title INITIATE: a multicentre, proof- of- concept, prospective interventional study
Countries of recruitment UK
Health condition or problem 
studied
Intermittent claudication
Intervention High- intensity interval training
Key inclusion and exclusion 
criteria
Ages eligible for the study: ≥18 years
Sexes eligible for the study: all
Accepts healthy volunteers: no
Inclusion criteria:
Community dwelling adults aged 18 or over.
ABPI <0.9 at rest or a drop of more than 20 mm Hg after exercise testing
Ability to walk unaided
English speaking and able to comply with exercise instructions
Exclusion Criteria:
Unable to provide informed consent
Critical limb threatening ischaemia/rest pain/tissue loss
Active cancer treatment
Significant comorbidities precluding safe participation in exercise testing and / or training 
according to the American College of Sports Medicine guidelines28
Resting/uncontrolled tachycardia (>100 bpm) and/or resting/uncontrolled hypertension (systolic 
blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg)
Symptomatic hypotension
Additional exclusion criteria: Exercise- induced myocardial ischaemia or significant haemodynamic compromise (manifesting 
as anginal symptoms, significant ECG changes or an abnormal blood pressure response).
Study type Interventional
Allocation: single group assignment
Primary purpose: Treatment
Date of first enrolment: 12/08/2019
Target sample size: 40 patients
Recruitment status: Recruiting
Primary outcomes: Safety: occurrence of adverse and serious adverse events
Feasibility: eligibility, recruitment and completion rates
Tolerability: assessing reasons for withdrawal, and identifying ability to reach and maintain the 
required intensity.
Secondary outcomes: Acceptability: patient feedback via semistructured interview
Efficacy: pain- free and maximal walking distance
Quality of life
Cardiorespiratory measures
Ankle brachial pressure index
ABPI, Ankle- Brachial Pressure Index.
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 ► Exercise- induced myocardial ischaemia or significant 
haemodynamic compromise (manifesting as anginal 
symptoms, significant ECG changes or an abnormal 
blood pressure response).
Study procedures
The participant pathway for the study is shown in figure 1. 
Briefly, patients who are deemed eligible for a usual SEP 
will be referred to the research team and their medical 
history reviewed to determine potential eligibility for 
INITIATE. Those appearing to meet the eligibility criteria 
will be sent an invitation letter and patient information 
sheet. Patients will then be contacted at least a week later 
via telephone to give them the opportunity to ask any 
questions and confirm if they are willing to participate. 
Those who decide to participate will be asked to attend 
a baseline visit where eligibility will be confirmed before 
informed consent is obtained. Those who decline the 
study will be offered SEP as per usual care.
Acceptability of the study and intervention will be 
assessed using qualitative interviews. The participant 
information sheet and consent form will include a clause 
that outlines the conduction of an interview with a subset 
of patients. The interview is optional, and participants can 
decline to be interviewed. Baseline and follow- up proce-
dures will include a full and detailed medical history, 
medication and symptom review, assessment of ABPI and 
a Gardner- Skinner graded treadmill test,30 followed by 
postexercise ABPI. For those who are confirmed eligible, 
spirometry and CPET will be subsequently undertaken. 
QoL measures will also be collected using the Medical 
Outcomes Study Short- Form 36 (SF-36) and the Kings 
College Hospitals Vascular QoL (VascuQoL) Question-
naires, both of which have demonstrated good reliability 
and validity in this patient population.31 32 Following base-
line CPET, exercise ECG and haemodynamic response will 
be evaluated to reassess eligibility to undergo HIIT. Those 
who exhibit exercise- induced ischaemia or an abnormal 
haemodynamic response to volitional exhaustion will 
be withdrawn from the study and referred back to the 
vascular consultant/required specialty as appropriate. 
Given CPET is not part of routine care, all patients will 
sign informed consent prior to undergoing it. Measure-
ments will be taken before starting the programme 
(baseline/week 0), immediately after completing the 
programme (week 6), then 12 weeks later (week 18). A 
further follow- up will be conducted 4 weeks (week 10) 
after programme completion at the Hull site only.
Intervention
This study will adapt a pragmatic and flexible HIIT 
protocol, based on a similar protocol currently being 
investigated in those with coronary artery disease.33 
Patients will attend three HIIT sessions per week for a 
period of 6 weeks, totalling 18 sessions. If participants 
miss sessions, the intervention period can be extended 
for up to two additional weeks to allow these sessions to 
be completed. Those not completing 18 sessions over the 
extended 8- week period will be deemed to have satisfac-
torily completed the intervention as long as they have 
undertaken >80% of the HIIT sessions (ie, ≥15 out of 18 
sessions). All patients completing the allotted 6–8 weeks 
for the intervention (regardless of whether they have 
completed ≥or <15 sessions) will be followed up. Those 
selecting to discontinue the intervention prematurely will 
be withdrawn, but the information collected up to their 
withdrawal will be retained and may still be used.
The intervention will be performed using a cycle 
ergometer (Wattbike Trainer, Wattbike, Nottingham, 
UK), with exercise prescription based on the peak work-
load achieved during the cycle CPET at baseline. Varia-
tions from high to low intensity cycling will be achieved 
by altering the cycle cadence (rpm). Although walking 
is often the recommended mode of exercise for those 
with IC and a treadmill based HIIT programme has been 
previously considered,34 35 a cycle was chosen for the 
current investigation for a number of reasons. First, the 
use of a treadmill may preclude patients from reaching 
their prescribed HIIT training zones due to limiting clau-
dication pain. Stationary cycling may also reduce the risk 
of falls, given the balance limitation often experienced by 
patients with IC.36 In addition, it has been demonstrated 
that the limiting symptoms during treadmill walking are 
often experienced in the leg, predominantly the calf, 
whereas the limiting symptoms during cycling are much 
more varied.37 Finally, it has also been noted that cycle 
testing is better tolerated than treadmill testing in those 
with IC, which is important considering that the HIIT 
training zone requires the patient to exercise intermit-
tently to near- peak exertion levels.38
Our HIIT work to rest ratio will be 1:1 (1 min high- 
intensity work interspaced with 1 min of low- intensity 
work), with patients completing 10 intervals for an overall 
exercise session time of 20 min. If required, a titrated intro-
duction to the HIIT programme will be used with fewer 
exercise intervals being completed in the first 2 weeks. 
Patients will also be allowed to complete less than 10 inter-
vals for longer than the first 2 weeks if required but will 
be encouraged to complete 10 as soon as possible there-
after. HIIT workloads will be set at 85%–90% of the peak 
power output achieved during the baseline CPET. Appli-
cation of this workload aims to achieve 85%–100% peak 
heart rate (HRpeak) from CPET by the end of the second 
interval. Our personal experience with cardiac patients 
has demonstrated that patients may exceed their HRpeak 
(from baseline CPET) during HIIT sessions. This is also 
likely to be the case for those with IC, especially those 
who are unable to achieve a maximal effort CPET. We will 
adopt a pragmatic approach to this by allowing it to occur 
without adjusting workload but will monitor on a case- by- 
case basis and reduce cycling intensity when it is deemed 
appropriate. We will also record these occurrences to 
allow appropriate reporting. All sessions will be preceded 
and followed by a 10 min warm- up and cool- down as is 
standard practice for exercise rehabilitation for older 
adults with chronic disease.
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Figure 1 Participant study flow. HIIT, high- intensity interval training; IC, intermittent claudication; SEP, supervised exercise 
programme
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outcome measures
Primary outcomes
The primary outcomes for this study are safety, feasibility 
and tolerability.
Safety will be assessed by determining the occurrence 
of any adverse or serious adverse events related to the 
intervention or study procedures. These events will be 
recorded in accordance with the Good Clinical Practice 
(GCP) decision tree for adverse event reporting and 
where applicable events will be reported to the sponsor 
and/or research ethics committee.
Feasibility will be assessed by considering eligibility (n = 
eligible/screened), recruitment (n = recruited/eligible) 
and adherence (n = completed/recruited). As such, the 
number of patients screened, recruited, commencing 
and completing (either satisfactorily or unsatisfactorily) 
the HIIT programme will be monitored at each site.
Tolerability will be assessed by considering reasons for 
withdrawal (ie, if they are related to the intervention) 
and identifying the number of patients able to reach and 
maintain the required intensity (ie, ≥85% HRMax by the 
end of the second interval) for the full 10 intervals. Toler-
ability will also assess whether patients can complete the 
full 10 intervals by the end of the second week.
Secondary outcomes
Secondary outcome measures include, acceptability, 
pain- free and maximal walking distance, ABPI, QoL and 
cardiorespiratory measures, collected during CPET.
Acceptability
will be assessed by conducting semistructured interviews 
at both sites using a sample of patients in three groups:
Group 1: Patients who are eligible for the study but 
decide not to participate (non- consenters). The inter-
views will explore reasons why patients chose not to 
participate in the study and whether study material could 
be amended to be more appealing. As these patients have 
declined participation in the study, they will sign an inter-
view specific consent form.
Group 2: Those who agree to participate in, and 
complete, the exercise programme (completers). The 
interviews will explore patient’s experiences of the HIIT 
programme, how acceptable they found it, whether they 
enjoyed it and whether they would be willing to under-
take it again. They will also be asked to provide informa-
tion related to potential barriers to participation in the 
programme and study, and any changes they may feel are 
required.
Group 3: Those who agree to participate but discon-
tinued after at least one session (withdrawals). Patients 
will be asked about their reasons for discontinuation and 
what, if anything, could have been modified to prevent 
withdrawal from the study.
An interview topic guide with a predetermined set of 
open questions will be used but the interviews will be 
flexible to allow the interviewer to ask further probing 
questions based on patient responses, and for patients 
to raise issues not explicitly covered by the topic guide. 
All interviews will be audio recorded using a Dictaphone, 
transcribed verbatim and anonymised.
Pain-free and maximal walking distance
Pain- free and maximal walking distance will be deter-
mined using the Gardner/Skinner treadmill test which 
starts at 2.0 mp/hour and 0% gradient, with gradient 
increasing by 2% every 2 min, while the speed remains 
constant, up to a maximum of 15 min. For those unable 
to walk on the treadmill at 2.0 mp/hour the speed will 
be reduced, but this speed will remain consistent at all 
follow- up visits to ensure standardisation. Patients will 
indicate when they begin to feel IC pain, which will be 
recorded as pain- free walking distance and the patient 
will continue until the pain is too severe and they need to 
stop, which will be recorded as maximal walking distance. 
Patients able to walk for 15 min will be excluded.
Quality of life
QoL will be assessed with both a generic and disease 
specific questionnaire. The SF-36 will be used as it is 
recommended as the most appropriate generic tool for 
those with lower limb ischaemia.39 The SF-36 gives a 
scoring profile across eight domains, ranging from 0 to 
100, with 0 indicating worst possible health and 100 best 
possible health. Scales can also be combined to create a 
physical and mental component summary.
The disease- specific questionnaire will be the VascuQoL 
which was designed for use in studies involving patients 
with lower limb ischaemia. It contains 25 items subdi-
vided into 5 domains, which are rated on a 7- point scale 
with 1 representing the worst score and 7 the best. A sum 
score is also calculated by dividing the total score by 25.
Cardiorespiratory measures
Cardiorespiratory function will be assessed at each time 
point using an individualised ramp based cycle CPET, 
conducted in accordance with international guide-
lines.40 41 Patients will be screened for contraindications 
to CPET and continuously monitored for indications for 
termination as per the ACSM guidelines.29 The CPET 
will be preceded by a 3 min period of rest on the bike to 
obtain resting measurements followed by a 3 min refer-
ence period of unloaded cycling followed by a progres-
sive individualised ramp protocol designed to elicit 
volitional exhaustion within 8–12 min, concluding with a 
recovery period.41 Patients will be encouraged to main-
tain 65–70 rpm throughout the test until they are limited 
by volitional fatigue. Monitoring will be via 12- lead ECG, 
blood pressure, oxygen saturation and rating of perceived 
exertion (RPE). Attainment of a maximal effort will be 
considered if the patient achieves 2 out of the following 
three criteria; achieving≥85% age- predicted maximum 
heart rate, a respiratory exchange ratio>1.10 and an 
RPE >17.42 However, based on a previous study, ∼25% of 
patients with IC are unable to achieve this, meaning it will 
not be applied as an exclusion and patients will continue 
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in the study, regardless of whether it is achieved.26 Breath- 
by- Breath gas analysis will be conducted (MedGraphics 
Ultima2 Medgraphics, St Paul, Minnesota, USA or Ergo-
stick, LoveMedical, Manchester, UK) to allow determina-
tion of a number of cardiorespiratory fitness parameters.
Ankle-Brachial Pressure Index
The systolic blood pressure will be measured bilaterally 
in the brachial, dorsalis pedis and posterial tibial arteries 
using a hand- held doppler and appropriately sized sphyg-
momanometer, with ABPI determined by dividing the 
higher ankle pressure of each leg with the highest arm 
pressure. Patients will be deemed eligible if they have 
an ABPI of <0.9 or a postexercise systolic blood pressure 
drop at the ankle of≥20 mm Hg.
sample size
As this feasibility proof- of- concept study does not aim to 
make any statistical comparison nor estimate an SD for 
future power calculations, there is no formal sample size 
requirement. We aim to recruit 20 patients from each site 
over the recruitment period, for a total of 40 patients.
data collection and management
Data will be collected by the study team across 3/4 time 
points dependant on site. Data will be collected contin-
uously for the qualitative study, based on the time at 
which patients decline, withdraw from or complete the 
intervention, until the point of data saturation. Data 
will be collected and retained in accordance with the 
General Data Protection Regulation (2018). All patients 
will be given a study code to ensure anonymity. Data will 
be stored via paper case report forms (CRFs) in code- 
secured research offices at the vascular laboratory in 
Hull Royal Infirmary and Coventry and Warwickshire 
University Hospital respectively with the same identifi-
cation code. These CRFs will be periodically scanned 
and sent to the team at Hull Royal Infirmary, who will 
manage the electronic and physical database, via email 
with end- to- end encryption. This database will be stored 
on a computer in the code- secured research office that 
is password protected and has both antivirus and firewall 
software. Only authorised members of the research team 
will have access to the patient data and transfer of data 
will be via Trust encrypted, password- protected remote 
storage devices or secure  nhs. net mail. Only authorised 
members of the research team will have access to the final 
dataset which will be stored for 5 years following study 
completion.
data analysis
Where applicability allows, the study will be reported in 
accordance with the Consolidated Standards of Reporting 
Trials (2010) statement extension to pilot and feasibility 
studies.43 Descriptive statistics will be reported for our feasi-
bility, tolerability and safety (proof- of- concept) outcomes. 
Descriptive statistics for our secondary outcomes will be 
reported to inform potential future studies in terms of 
clinical and QoL outcome measures.
The qualitative data will be analysed using an inductive 
thematic analysis, whereby themes are identified from 
within the data.44 The researcher will read and reread 
the transcripts to identify patterns of responses within the 
data that are related to the research question and can be 
grouped together under a theme heading. The approach 
will be inductive, which means that the themes are data 
driven, thus emerging from the data, and do not fit into a 
pre- existing coding frame.44
Patient and public involvement
The background patient and public involvement (PPI) 
work for this study was supported by a grant from the 
NIHR Research Design Service Yorkshire and the Humber. 
Consequently, two focus group sessions, each involving 
five patients with a confirmed diagnosis of IC and expe-
rience of undertaking a standard SEP, were conducted 
which informed the design of this study. In addition, 
this PPI group is committed to continuous contribution 
during the research study, with the chair of the PPI group 
invited to attend all trial steering committee meetings. 
We also aim to hold 3–4 PPI meetings over the course of 
the study to aid with addressing potential recruitment or 
retention issues and aid with dissemination of the study 
findings.
EthICs And dIssEMInAtIon
Protocol approval was obtained via a local NHS research 
ethics committee (Bradford Leeds – 18/YH/0112) and 
all patients will provide informed consent prior to partic-
ipation, which will be obtained by study personnel with 
appropriate GCP training.
On completion, study results will be published in peer- 
reviewed journals and presented at international scien-
tific meetings. In addition, with our PPI group, we will 
disseminate findings to the public, which will include lay 
summaries to participants and vascular charities such as 
the Circulation Foundation (Registered Charity Number: 
1102769). The expected impact for this study is the devel-
opment of a new time- efficient exercise programme 
for patients with IC, which is more acceptable, thus 
improving uptake and adherence. Should this study 
support the feasibility of HIIT for patients with IC, we aim 
to undertake a multicentre, pilot randomised controlled 
trial comparing HIIT to standard SEPs, which can inform 
a definitive trial, which has potential to impact on inter-
national guidelines.
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